Zhenghua H. Zhang - Publications

Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis with a high drug interruption rate during the COVID-19 pandemic: a post hoc analysis from a single center of a phase III trial.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: April 16, 2026

Lesional sweat interleukin-17A reflects local inflammatory activity and treatment response in plaque psoriasis.

Journal: The British journal of dermatology

Published: April 01, 2026

PD-1 Engagement and Circulating Th17 Effector Activity During Secukinumab Treatment in Plaque Psoriasis.

Journal: Clinical and experimental immunology

Published: February 23, 2026

A rare severe acrodermatitis continua of Hallopeau treated with spesolimab.

Journal: The Journal of dermatology

Published: October 08, 2024

Establishment of a Mouse Model for Porokeratosis Due to Mevalonate Diphosphate Decarboxylase Deficiency.

Journal: Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)

Published: July 16, 2024

Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial.

Journal: Journal of the American Academy of Dermatology

Published: May 03, 2024

Differential expression of plasma extracellular vesicle miRNAs as biomarkers for distinguishing psoriatic arthritis from psoriasis.

Journal: Chinese medical journal

Published: November 24, 2023

Identification of an exosomal miRNA-mRNA regulatory network contributing to methotrexate efficacy.

Journal: International immunopharmacology

Published: August 12, 2023

Comparison and subsets analysis of peripheral CD4+T cells in patients with psoriasis and psoriatic arthritis.

Journal: Molecular immunology

Published: June 29, 2023

Unlocking the role of the B7-H4 polymorphism in psoriasis: Insights into methotrexate treatment outcomes: A prospective cohort study.

Journal: Immunology

Published: June 25, 2023

Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension.

Journal: Chinese medical journal

Published: June 24, 2023

Effective treatment of solar facial porokeratosis in one patient with topical atorvastatin/cholesterol cream.

Journal: Clinical and experimental dermatology

Published: May 17, 2023